A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab in Prurigo Nodularis

To join this study, you need to be an adult at least 18 years old and have been diagnosed with prurigo nodularis for at least 3 months. You should have at least 20 itchy lumps (nodules) on your body, for example, on both your arms, legs, or torso. Also, you must have tried and not responded well to strong skin creams, or your doctor has advised against using them for safety reasons.

There are also some reasons why you might not be able to join. For instance, if you have other skin or body conditions that could make it difficult to properly check the study results, or if your prurigo nodularis is caused by certain medicines, nerve problems, or mental health conditions, you might not be eligible. Also, if you've recently taken certain strong medicines that affect your immune system, or had live vaccines, you might need to wait a while before you can participate.

If you decide to take part in this study, you would receive either the new medicine, rocatinlimab, or a placebo (a dummy medicine). Neither you nor your study doctor will know which one you are getting. You would have regular appointments at the study clinic, where doctors and nurses would check your health, assess your skin condition, and ask about your itching levels. You'd also be asked to keep a daily diary of your itching. These visits would happen over a period of 24 weeks, followed by further checks to monitor your progress and safety. The full duration of your participation would involve regular check-ups and assessments, both while you're receiving the study medicine and for a period afterwards to ensure your well-being.